Role of Toll‑like receptors in natural killer cell function in acute lymphoblastic leukemia (Review)
- Authors:
- Janet Gallardo‑Zapata
- Carmen Maldonado‑Bernal
-
Affiliations: Immunology and Proteomics Research Unit, Children's Hospital of Mexico Federico Gómez, Mexico City 06720, Mexico - Published online on: August 24, 2021 https://doi.org/10.3892/ol.2021.13009
- Article Number: 748
-
Copyright: © Gallardo‑Zapata et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
Timonen BYT, Ortaldo JR and Herberman RB: Characteristics of human large granular lymphocytes and relationship to natural killer and K cells. J Exp Med. 153:569–582. 1981. View Article : Google Scholar : PubMed/NCBI | |
Galy A, Travis M, Cen D and Chen B: Human T, B, natural killer, and dendritic cells arise from a common bone marrow progenitor cell subset. Immunity. 3:459–473. 1995. View Article : Google Scholar : PubMed/NCBI | |
Scoville SD, Freud AG and Caligiuri MA: Modeling human natural killer cell development in the era of innate lymphoid cells. Front Immunol. 8:3602017. View Article : Google Scholar : PubMed/NCBI | |
Nitta T, Yagita H, Sato K and Okumura K: Involvement of CD56 (NKH-1/Leu-19 antigen) as an adhesion molecule in natural killer-target cell interaction. J Exp Med. 170:1757–1761. 1989. View Article : Google Scholar : PubMed/NCBI | |
Lanier LL, Le AM, Civin CI, Loken MR and Phillips JH: The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J Immunol. 136:4480–4486. 1986.PubMed/NCBI | |
Vivier E, Artis D, Colonna M, Diefenbach A, Di Santo JP, Eberl G, Koyasu S, Locksley RM, McKenzie ANJ, Mebius RE, et al: Innate lymphoid cells: 10 years on. Cell. 174:1054–1066. 2018. View Article : Google Scholar : PubMed/NCBI | |
Chiorean EG and Miller JS: The biology of natural killer cells and implications for therapy of human disease. J Hematotherapy Stem Cell Res. 10:451–463. 2001. View Article : Google Scholar : PubMed/NCBI | |
Fauriat C, Long EO, Ljunggren HG and Bryceson YT: Regulation of human NK-cell cytokine and chemokine production by target cell recognition. Blood. 115:2167–2176. 2010. View Article : Google Scholar : PubMed/NCBI | |
Lotze MT and Thomson AW: Natural killer cells: Basic science and clinical application. Academic Press; 2009 | |
Reeves RK, Li H, Jost S, Blass E, Li H, Schafer JL, Varner V, Manickam C, Eslamizar L, Altfeld M, et al: Antigen-specific NK cell memory in rhesus macaques. Nat Immunol. 16:927–932. 2015. View Article : Google Scholar : PubMed/NCBI | |
Nikzad R, Angelo LS, Aviles-Padilla K, Le DT, Singh VK, Bimler L, Vukmanovic-Stejic M, Vendrame E, Ranganath T, Simpson L, et al: Human natural killer cells mediate adaptive immunity to viral antigens. Sci Immunol. 4:eaat81162019. View Article : Google Scholar : PubMed/NCBI | |
Freud AG, Yokohama A, Becknell B, Lee MT, Mao HC, Ferketich AK and Caligiuri MA: Evidence for discrete stages of human natural killer cell differentiation in vivo. J Exp Med. 203:1033–1043. 2006. View Article : Google Scholar : PubMed/NCBI | |
Rosmaraki EE, Douagi I, Roth C, Colucci F, Cumano A and Di Santo JP: Identification of committed NK cell progenitors in adult murine bone marrow. Eur J Immunol. 31:1900–1909. 2001. View Article : Google Scholar : PubMed/NCBI | |
Huntington ND, Vosshenrich CAJ and Di Santo JP: Developmental pathways that generate natural-killer-cell diversity in mice and humans. Nat Rev Immunol. 7:703–714. 2007. View Article : Google Scholar : PubMed/NCBI | |
Cooper MA, Fehniger TA and Caligiuri MA: The biology of human natural killer-cell subsets. Trends Immunol. 22:633–640. 2001. View Article : Google Scholar : PubMed/NCBI | |
Poli A, Michel T, Thérésine M, Andrès E, Hentges F and Zimmer J: CD56bright natural killer (NK) cells: An important NK cell subset. Immunology. 126:458–465. 2009. View Article : Google Scholar : PubMed/NCBI | |
Cooper MA, Fehniger TA, Turner SC, Chen KS, Ghaheri BA, Carson WE and Caligiuri MA: Human natural killer cells: A unique innate immunoregulatory role for the CD56bright subset. Blood. 96:3146–3151. 2000. | |
Nagler A, Lanier LL, Cwirla S and Phillips JH: Comparative studies of human FcRIII-positive and negative natural killer cells. J Immunol. 143:3183–3191. 1989.PubMed/NCBI | |
Caligiuri MA, Murray C, Robertson MJ, Wang E, Cochran K, Cameron C, Schow P, Ross ME, Klumpp TR, Soiffer RJ, et al: Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. J Clin Invest. 91:123–132. 1993. View Article : Google Scholar : PubMed/NCBI | |
Mrózek E, Anderson P and Caligiuri MA: Role of interleukin-15 in the development of human CD56+ natural killer cells from CD34+ hematopoietic progenitor cells. Blood. 87:2632–2640. 1996. View Article : Google Scholar : PubMed/NCBI | |
Frey M, Packianathan NB, Fehniger TA, Ross ME, Wang WC, Stewart CC, Caligiuri MA and Evans SS: Differential expression and function of L-selectin on CD56bright and CD56dim natural killer cell subsets. J Immunol. 161:400–408. 1998.PubMed/NCBI | |
Berahovich RD, Lai NL, Wei Z, Lanier LL and Schall TJ: Evidence for NK cell subsets based on chemokine receptor expression. J Immunol. 177:7833–7840. 2006. View Article : Google Scholar : PubMed/NCBI | |
Chan A, Hong DL, Atzberger A, Kollnberger S, Filer AD, Buckley CD, McMichael A, Enver T and Bowness P: CD56bright human NK cells differentiate into CD56dim cells: Role of contact with peripheral fibroblasts. J Immunol. 179:89–94. 2007. View Article : Google Scholar : PubMed/NCBI | |
Béziat V, Duffy D, Quoc SN, Le Garff-Tavernier M, Decocq J, Combadière B, Debré P and Vieillard V: CD56brightCD16+ NK cells: A functional intermediate stage of NK cell differentiation. J Immunol. 186:6753–6761. 2011. View Article : Google Scholar : PubMed/NCBI | |
Vivier E, Tomasello E, Baratin M, Walzer T and Ugolini S: Functions of natural killer cells. Nat Immunol. 9:503–510. 2008. View Article : Google Scholar : PubMed/NCBI | |
Smyth MJ, Cretney E, Kelly JM, Westwood JA, Street SE, Yagita H, Takeda K, van Dommelen SL, Degli-Esposti MA and Hayakawa Y: Activation of NK cell cytotoxicity. Mol Immunol. 42:501–510. 2005. View Article : Google Scholar : PubMed/NCBI | |
Krzewski K and Strominger JL: The killer's kiss: The many functions of NK cell immunological synapses. Curr Opin Cell Biol. 20:597–605. 2008. View Article : Google Scholar : PubMed/NCBI | |
Guicciardi ME and Gores GJ: Life and death by death receptors. FASEB J. 23:1625–1637. 2009. View Article : Google Scholar : PubMed/NCBI | |
Abel AM, Yang C, Thakar MS and Malarkannan S: Natural killer cells: Development, maturation, and clinical utilization. Front Immunol. 9:1–23. 2018. View Article : Google Scholar : PubMed/NCBI | |
Barry M, Heibein JA, Pinkoski MJ, Lee SF, Moyer RW, Green DR and Bleackley RC: Granzyme B short-circuits the need for caspase 8 activity during granule-mediated cytotoxic T-lymphocyte killing by directly cleaving Bid. Mol Cell Biol. 20:3781–3794. 2000. View Article : Google Scholar : PubMed/NCBI | |
Pinkoski MJ, Waterhouse NJ, Heibein JA, Wolf BB, Kuwana T, Goldstein JC, Newmeyer DD, Bleackley RC and Green DR: Granzyme B-mediated apoptosis proceeds predominantly through a Bcl-2-inhibitable mitochondrial pathway. J Biol Chem. 276:12060–12067. 2001. View Article : Google Scholar : PubMed/NCBI | |
Amand M, Iserentant G, Poli A, Sleiman M, Fievez V, Sanchez IP, Sauvageot N, Michel T, Aouali N, Janji B, et al: Human CD56dimCD16dim cells as an individualized natural killer cell subset. Front Immunol. 8:6992017. View Article : Google Scholar : PubMed/NCBI | |
Iannello A and Ahmad A: Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies. Cancer Metastasis Rev. 24:487–499. 2005. View Article : Google Scholar : PubMed/NCBI | |
Zambello R, Falco M, Della Chiesa M, Trentin L, Carollo D, Castriconi R, Cannas G, Carlomagno S, Cabrelle A, Lamy T, et al: Expression and function of KIR and natural cytotoxicity receptors in NK-type lymphoproliferative diseases of granular lymphocytes. Blood. 102:1797–1805. 2003. View Article : Google Scholar : PubMed/NCBI | |
Bryceson YT, March ME, Ljunggren HG and Long EO: Activation, coactivation, and costimulation of resting human natural killer cells. Immunol Rev. 214:73–91. 2006. View Article : Google Scholar : PubMed/NCBI | |
Li NL, Davidson CL, Humar A and Burshtyn DN: Modulation of the inhibitory receptor leukocyte Ig-like receptor 1 on human natural killer cells. Front Immunol. 2:462011.PubMed/NCBI | |
Ljunggren HG and Kärre K: In search of the ‘missing self’: MHC molecules and NK cell recognition. Immunol Today. 11:237–244. 1990. View Article : Google Scholar : PubMed/NCBI | |
Tomasello E, Blery M, Vely E and Vivier E: Signaling pathways engaged by NK cell receptors: Double concerto for activating receptors, inhibitory receptors and NK cells. Semin Immunol. 12:139–147. 2000. View Article : Google Scholar : PubMed/NCBI | |
Lanier LL: Up on the tightrope: Natural killer cell activation and inhibition. Nat Immunol. 9:495–502. 2008. View Article : Google Scholar : PubMed/NCBI | |
Blanca IR, Bere EW, Young HA and Ortaldo JR: Human B cell activation by autologous NK cells is regulated by CD40-CD40 ligand interaction: Role of memory B cells and CD5+ B cells. J Immunol. 167:6132–6139. 2001. View Article : Google Scholar : PubMed/NCBI | |
Zingoni A, Sornasse T, Cocks BG, Tanaka Y, Santoni A and Lanier LL: Cross-talk between activated human NK cells and CD4+ T cells via OX40-OX40 ligand interactions. J Immunol. 173:3716–3724. 2004. View Article : Google Scholar : PubMed/NCBI | |
Orange JS and Ballas ZK: Natural killer cells in human health and disease. Clin Immunol. 118:1–10. 2006. View Article : Google Scholar : PubMed/NCBI | |
Chalifour A, Jeannin P, Gauchat JF, Blaecke A, Malissard M, N'Guyen T, Thieblemont N and Delneste Y: Direct bacterial protein PAMP recognition by human NK cells involves TLRs and triggers α-defensin production. Blood. 104:1778–1783. 2004. View Article : Google Scholar : PubMed/NCBI | |
Perrot I, Deauvieau F, Massacrier C, Hughes N, Garrone P, Durand I, Demaria O, Viaud N, Gauthier L, Blery M, et al: TLR3 and Rig-like receptor on myeloid dendritic cells and Rig-like receptor on human NK cells are both mandatory for production of IFN-gamma in response to double-stranded RNA. J Immunol. 185:2080–2088. 2010. View Article : Google Scholar : PubMed/NCBI | |
Qiu F, Maniar A, Quevedo Diaz M, Chapoval AI and Medvedev AE: Activation of cytokine-producing and antitumor activities of natural killer cells and macrophages by engagement of Toll-like and NOD-like receptors. Innate Immun. 17:375–387. 2011. View Article : Google Scholar : PubMed/NCBI | |
Sivori S, Carlomagno S, Moretta L and Moretta A: Comparison of different CpG oligodeoxynucleotide classes for their capability to stimulate human NK cells. Eur J Immunol. 36:961–967. 2006. View Article : Google Scholar : PubMed/NCBI | |
Girart MV, Fuertes MB, Domaica CI, Rossi LE and Zwirner NW: Engagement of TLR3, TLR7, and NKG2D regulate IFN-gamma secretion but not NKG2D-mediated cytotoxicity by human NK cells stimulated with suboptimal doses of IL-12. J Immunol. 179:3472–3479. 2007. View Article : Google Scholar : PubMed/NCBI | |
Sivori S, Carlomagno S, Pesce S, Moretta A, Vitale M and Marcenaro E: TLR/NCR/KIR: Which one to use and when? Front Immunol. 5:1052014. View Article : Google Scholar : PubMed/NCBI | |
Saikh KU, Lee JS, Kissner TL, Dyas B and Ulrich RG: Toll-like receptor and cytokine expression patterns of CD56+ T cells are similar to natural killer cells in response to infection with Venezuelan equine encephalitis virus replicons. J Infect Dis. 188:1562–1570. 2003. View Article : Google Scholar : PubMed/NCBI | |
Lauzon NM, Mian F, MacKenzie R and Ashkar AA: The direct effects of Toll-like receptor ligands on human NK cell cytokine production and cytotoxicity. Cell Immunol. 241:102–112. 2006. View Article : Google Scholar : PubMed/NCBI | |
Becker I, Salaiza N, Aguirre M, Delgado J, Carrillo-Carrasco N, Kobeh LG, Ruiz A, Cervantes R, Torres AP, Cabrera N, et al: Leishmania lipophosphoglycan (LPG) activates NK cells through toll-like receptor-2. Mol Biochem Parasitol. 130:65–74. 2003. View Article : Google Scholar : PubMed/NCBI | |
Schmidt KN, Leung B, Kwong M, Zarember KA, Satyal S, Navas TA, Wang F and Godowski PJ: APC-independent activation of NK cells by the toll-like receptor 3 agonist double-stranded RNA. J Immunol. 172:138–143. 2004. View Article : Google Scholar : PubMed/NCBI | |
Sivori S, Falco M, Della Chiesa M, Carlomagno S, Vitale M, Moretta L and Moretta A: CpG and double-stranded RNA trigger human NK cells by toll-like receptors: Induction of cytokine release and cytotoxicity against tumors dendritic cells. Proc Natl Acad Sci USA. 101:10116–10121. 2004. View Article : Google Scholar : PubMed/NCBI | |
Gorski KS, Waller EL, Bjornton-Severson J, Hanten JA, Riter CL, Kieper WC, Gorden KB, Miller JS, Vasilakos JP, Tomai MA and Alkan SS: Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists. Int Immunol. 18:1115–1126. 2006. View Article : Google Scholar : PubMed/NCBI | |
Alter G, Suscovich TJ, Teigen N, Meier A, Streeck H, Brander C and Altfeld M: Single-stranded RNA derived from HIV-1 serves as a potent activator of NK cells. J Immunol. 178:7658–7666. 2007. View Article : Google Scholar : PubMed/NCBI | |
Mian MF, Lauzon NM, Andrews DW, Lichty BD and Ashkar AA: FimH can directly activate human and murine natural killer cells via TLR4. Mol Ther. 18:1379–1388. 2010. View Article : Google Scholar : PubMed/NCBI | |
He S, Chu J, Wu LC, Mao H, Peng Y, Alvarez-Breckenridge CA, Hughes T, Wei M, Zhang J, Yuan S, et al: MicroRNAs activate natural killer cells through Toll-like receptor signaling. Blood. 121:4663–4671. 2013. View Article : Google Scholar : PubMed/NCBI | |
Guo Q and Zhang C: Critical role of Toll-like receptor signaling in NK cell activation. Chinese Sci Bull. 57:3192–3202. 2012. View Article : Google Scholar | |
Adib-Conquy M, Scott-Algara D, Cavaillon JM and Souza-Fonseca-Guimaraes F: TLR-mediated activation of NK cells and their role in bacterial/viral immune responses in mammals. Immunol Cell Biol. 92:256–262. 2014. View Article : Google Scholar : PubMed/NCBI | |
Ljunggren HG and Malmberg KJ: Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol. 7:329–339. 2007. View Article : Google Scholar : PubMed/NCBI | |
Algarra I, García-Lora A, Cabrera T, Ruiz-Cabello F and Garrido F: The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: Implications for tumor immune escape. Cancer Immunol Immunother. 53:904–910. 2004. View Article : Google Scholar : PubMed/NCBI | |
Samarakoon A, Chu H and Malarkannan S: Murine NKG2D ligands:‘Double, double toil and trouble.’. Mol Immunol. 46:1011–1019. 2009. View Article : Google Scholar : PubMed/NCBI | |
Imai K, Matsuyama S, Miyake S, Suga K and Nakachi K: Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: An 11-year follow-up study of a general population. Lancet. 356:1795–1799. 2000. View Article : Google Scholar : PubMed/NCBI | |
Coca S, Perez-Piqueras J, Martinez D, Colmenarejo A, Saez MA, Vallejo C, Martos JA and Moreno M: The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer. 79:2320–2328. 1997. View Article : Google Scholar : PubMed/NCBI | |
Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Che X, Iwashige H, Aridome K, Hokita S and Aikou T: Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer. 88:577–583. 2000. View Article : Google Scholar : PubMed/NCBI | |
Villegas FR, Coca S, Villarrubia VG, Jiménez R, Chillón MJ, Jareño J, Zuil M and Callol L: Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung Cancer. 35:23–28. 2002. View Article : Google Scholar : PubMed/NCBI | |
Habif G, Crinier A, André P, Vivier E and Narni-Mancinelli E: Targeting natural killer cells in solid tumors. Cell Mol Immunol. 16:415–422. 2019. View Article : Google Scholar : PubMed/NCBI | |
Guillerey C, Huntington ND and Smyth MJ: Targeting natural killer cells in cancer immunotherapy. Nat Immunol. 17:1025–1036. 2016. View Article : Google Scholar : PubMed/NCBI | |
Vitale M, Cantoni C, Pietra G, Mingari MC and Moretta L: Effect of tumor cells and tumor microenvironment on NK-cell function. Eur J Immunol. 44:1582–1592. 2014. View Article : Google Scholar : PubMed/NCBI | |
Mushtaq MU, Papadas A, Pagenkopf A, Flietner E, Morrow Z, Chaudhary SG and Asimakopoulos F: Tumor matrix remodeling and novel immunotherapies: The promise of matrix-derived immune biomarkers. J Immunother Cancer. 6:652018. View Article : Google Scholar : PubMed/NCBI | |
Diermayr S, Himmelreich H, Durovic B, Mathys-Schneeberger A, Siegler U, Langenkamp U, Hofsteenge J, Gratwohl A, Tichelli A, Paluszewska M, et al: NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities. Blood. 111:1428–1436. 2008. View Article : Google Scholar : PubMed/NCBI | |
Chang MC, Cheng HI, Hsu K, Hsu YN, Kao CW, Chang YF, Lim KH and Chen CG: NKG2A down-regulation by dasatinib enhances natural killer cytotoxicity and accelerates effective treatment responses in patients with chronic myeloid leukemia. Front Immunol. 9:31522018. View Article : Google Scholar : PubMed/NCBI | |
Sanchez-Correa B, Morgado S, Gayoso I, Bergua JM, Casado JG, Arcos MJ, Bengochea ML, Duran E, Solana R and Tarazona R: Human NK cells in acute myeloid leukaemia patients: Analysis of NK cell-activating receptors and their ligands. Cancer Immunol Immunother. 60:1195–1205. 2011. View Article : Google Scholar : PubMed/NCBI | |
Rouce RH, Shaim H, Sekine T, Weber G, Ballard B, Ku S, Barese C, Murali V, Wu MF, Liu H, et al: The TGF-β/SMAD pathway is an important mechanism for NK cell immune evasion in childhood B-acute lymphoblastic leukemia. Leukemia. 30:800–811. 2016. View Article : Google Scholar : PubMed/NCBI | |
Valenzuela-Vazquez L, Núñez-Enríquez JC, Sánchez-Herrera J, Jiménez-Hernández E, Martín-Trejo JA, Espinoza-Hernández LE, Medina-Sanson A, Flores-Villegas LV, Peñaloza-González JG, Refugio Torres-Nava J, et al: Functional characterization of NK cells in Mexican pediatric patients with acute lymphoblastic leukemia: Report from the Mexican Interinstitutional Group for the Identification of the Causes of Childhood Leukemia. PLoS One. 15:e02273142020. View Article : Google Scholar : PubMed/NCBI | |
Jarosz M, Hak Ł, Więckiewicz J, Balcerska A and Myśliwska J: Clinical immunology NK cells in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma after cessation of intensive chemotherapy. Cent Eur J Immunol. 34:94–99. 2009. | |
Hsu KC, Keever-Taylor CA, Wilton A, Pinto C, Heller G, Arkun K, O'Reilly RJ, Horowitz MM and Dupont B: Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood. 105:4878–4884. 2005. View Article : Google Scholar : PubMed/NCBI | |
Fei F, Lim M, George AA, Kirzner J, Lee D, Seeger R, Groffen J, Abdel-Azim H and Heisterkamp N: Cytotoxicity of CD56-positive lymphocytes against autologous B-cell precursor acute lymphoblastic leukemia cells. Leukemia. 29:788–797. 2015. View Article : Google Scholar : PubMed/NCBI | |
Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, et al: Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 378:439–448. 2018. View Article : Google Scholar : PubMed/NCBI | |
Park JH, Rivière I, Gonen M, Wang X, Sénéchal B, Curran KJ, Sauter C, Wang Y, Santomasso B, Mead E, et al: Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 378:449–459. 2018. View Article : Google Scholar : PubMed/NCBI | |
Li L, Liu LN, Feller S, Allen C, Shivakumar R, Fratantoni J, Wolfraim LA, Fujisaki H, Campana D, Chopas N, et al: Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method. Cancer Gene Ther. 17:147–154. 2010. View Article : Google Scholar : PubMed/NCBI | |
Shimasaki N, Fujisaki H, Cho D, Masselli M, Lockey T, Eldridge P, Leung W and Campana D: A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies. Cytotherapy. 14:830–840. 2012. View Article : Google Scholar : PubMed/NCBI | |
Xie G, Dong H, Liang Y, Ham JD, Rizwan R and Chen J: CAR-NK cells: A promising cellular immunotherapy for cancer. EBioMedicine. 59:1029752020. View Article : Google Scholar : PubMed/NCBI | |
Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, Nassif Kerbauy L, Overman B, Thall P, Kaplan M, et al: Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med. 382:545–553. 2020. View Article : Google Scholar : PubMed/NCBI | |
Sánchez-Cuaxospa M, Contreras-Ramos A, Pérez-Figueroa E, Medina-Sansón A, Jiménez-Hernández E, Torres-Nava JR, Rojas-Castillo E and Maldonado-Bernal C: Low expression of Toll-like receptors in peripheral blood mononuclear cells of pediatric patients with acute lymphoblastic leukemia. Int J Oncol. 49:675–681. 2016. View Article : Google Scholar : PubMed/NCBI | |
Samudio I, Rezvani K, Shaim H, Hofs E, Ngom M, Bu L, Liu G, Lee JT, Imren S, Lam V, et al: UV-inactivated HSV-1 potently activates NK cell killing of leukemic cells. Blood. 127:2575–2586. 2016. View Article : Google Scholar : PubMed/NCBI | |
Flavell DJ, Holmes SE, Warnes SL and Flavell SU: The TLR3 agonist poly inosinic: Cytidylic acid significantly augments the therapeutic activity of an anti-CD7 immunotoxin for human T-cell leukaemia. Biomedicines. 7:132019. View Article : Google Scholar : PubMed/NCBI | |
Cheadle EJ, Lipowska-Bhalla G, Dovedi SJ, Fagnano E, Klein C, Honeychurch J and Illidge TM: A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells. Leukemia. 31:1611–1621. 2017. View Article : Google Scholar : PubMed/NCBI | |
Kim H, Khanna V, Kucaba TA, Zhang W, Sehgal D, Ferguson DM, Griffith TS and Panyam J: TLR7/8 agonist loaded nanoparticles augment NK Cell-mediated Antibody-based cancer immunotherapy. Mol Pharm. 17:2109–2124. 2020. View Article : Google Scholar : PubMed/NCBI | |
Ronsley R, Kariminia A, Ng B, Mostafavi S, Reid G, Subrt P, Hijiya N and Schultz KR: The TLR9 agonist (GNKG168) induces a unique immune activation pattern in vivo in children with minimal residual disease positive acute leukemia: Results of the TACL T2009-008 phase I study. Pediatr Hematol Oncol. 36:468–481. 2019. View Article : Google Scholar : PubMed/NCBI |